Amgen and Novartis back Aimovig with new data as migraine competition heats up
Facing a slew of competitors, Amgen and Novartis are marching out new Phase IV results to bolster Aimovig, their first-to-market CGRP inhibitor for migraine prevention.
The results come about a year and a half after the drug was panned by a group of medical experts who convened at UnitedHealth Group’s OptumRx offices, concluding it and two other drugs had no clear benefit over existing treatments. The panel suggested that US insurers impose limits on its use, as well as Teva’s Ajovy and Eli Lilly’s Emgality, all approved in 2018, according to a Reuters report.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.